-transparent.png){kind=logo}
Clinically used dosage regimen of nitroxoline, three times 100 mg daily, was proved to be inappropriate because the successfulness of medical treatment was rarely sufficient. Nitroxoline, used as urinary antiseptic, exhibits its antibacterial activity in concentrations higher than 6 mg/l, as demonstrated in many "in vitro" experiments. This work deals with the most appropriate nitroxoline dosage form as well as with the optimal dosage regimen design. The data were obtained by the aid of the suitable pharmacokinetic model and multiple dosing simulation on analog-hybrid computer EAI 580. From the several studied alternatives two usable dosage forms with the necessary dose and corresponding dosage interval were selected.
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
January 1982,
Pharmacology & therapeutics,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
July 1992,
Journal of clinical pharmacology,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
March 1992,
Journal of clinical pharmacology,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
September 1986,
Journal of pharmaceutical sciences,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
July 1985,
Methods and findings in experimental and clinical pharmacology,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
January 1997,
The Journal of clinical psychiatry,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
January 1965,
Chemotherapy,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
January 1965,
Chemotherapy,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
January 1982,
Arzneimittel-Forschung,
R Karba, and
A Mrhar, and
F Kozjek, and
F Bremsak
July 1975,
Clinical pharmacology and therapeutics,
